Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers

NCT00002515 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT00002515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
October 31, 1992
Completion date
April 30, 2005
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

childhood germ cell tumor, extragonadal germ cell tumor, head and neck cancer, kidney cancer, liver cancer, lymphoma, neuroblastoma, ovarian cancer, retinoblastoma, sarcoma, testicular germ cell tumor